Priming after a fractional dose of inactivated poliovirus vaccine.
BACKGROUND
To reduce the costs of maintaining a poliovirus immunization base in low-income areas, we assessed the extent of priming immune responses after the administration of inactivated poliovirus vaccine (IPV).


METHODS
We compared the immunogenicity and reactogenicity of a fractional dose of IPV (one fifth of a full dose) administered intradermally with a full dose administered intramuscularly in Cuban infants at the ages of 4 and 8 months. Blood was collected from infants at the ages of 4 months, 8 months, 8 months 7 days, and 8 months 30 days to assess single-dose seroconversion, single-dose priming of immune responses, and two-dose seroconversion. Specimens were tested with a neutralization assay.


RESULTS
A total of 320 infants underwent randomization, and 310 infants (96.9%) fulfilled the study requirements. In the group receiving the first fractional dose of IPV, seroconversion to poliovirus types 1, 2, and 3 occurred in 16.6%, 47.1%, and 14.7% of participants, respectively, as compared with 46.6%, 62.8%, and 32.0% in the group receiving the first full dose of IPV (P<0.008 for all comparisons). A priming immune response to poliovirus types 1, 2, and 3 occurred in 90.8%, 94.0%, and 89.6% of participants, respectively, in the group receiving the fractional dose as compared with 97.6%, 98.3%, and 98.1% in the group receiving the full dose (P=0.01 for the comparison with type 3). After the administration of the second dose of IPV in the group receiving fractional doses, cumulative two-dose seroconversion to poliovirus types 1, 2, and 3 occurred in 93.6%, 98.1%, and 93.0% of participants, respectively, as compared with 100.0%, 100.0%, and 99.4% in the group receiving the full dose (P<0.006 for the comparisons of types 1 and 3). The group receiving intradermal injections had the greatest number of adverse events, most of which were minor in intensity and none of which had serious consequences.


CONCLUSIONS
This evaluation shows that vaccinating infants with a single fractional dose of IPV can induce priming and seroconversion in more than 90% of immunized infants. (Funded by the World Health Organization and the Pan American Health Organization; Australian New Zealand Clinical Trials Registry number, ACTRN12610001046099.).
Pedro Kouri Institute, Havana, Cuba.
Sonia
S
Resik
Alina
A
Tejeda
Roland W
RW
Sutter
Manuel
M
Diaz
Luis
L
Sarmiento
Nilda
N
Alemañi
Gloria
G
Garcia
Magilé
M
Fonseca
Lai Heng
LH
Hung
Anna-Lea
AL
Kahn
Anthony
A
Burton
J Mauricio
JM
Landaverde
R Bruce
RB
Aylward
D000914:Antibodies, Viral / Q000097:blood*; D003462:Cuba; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D016036:Seroepidemiologic Studies
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated